bifidobacterium bifidum VDD088

**bifidobacterium bifidum VDD088** is a specific probiotic strain of the species Bifidobacterium bifidum, isolated from a healthy infant gut and deposited as CGMCC No. 15211. It has been studied primarily as part of a multi-strain probiotic formulation (with Lactobacillus acidophilus TYCA06 and Bifidobacterium longum subsp. infantis BLI-02) for its effects on kidney function, inflammation, glucose homeostasis, and gut microbiota, especially in the context of chronic kidney disease (CKD) and diabetic nephropathy. The mechanisms associated with this strain include antioxidation, anti-inflammation, glucose metabolism modulation, and inhibition of harmful indole/indoxyl sulfate production by limiting pathogenic gut bacteria such as Escherichia coli. It is considered food-grade and is administered orally in capsule formulations or as a component in dietary products. Clinical and preclinical studies indicate benefits in reducing uremic toxins, improving renal dysfunction indicators, reducing inflammatory cytokines, and promoting favorable changes in the gut microbiota in both human and animal models[1][2][3].

Other names

CGMCC No. 15211